Novel biomarkers assessing renal function in heart failure: Relation to inflammatory status and cardiac remodelling

Current Medicinal Chemistry

Volumn 21, Issue 34, 2014, Pages 3976-3983

  Siasos, Gerasimos ^a   Tousoulis, Dimitris ^a   Michalea, Stavroula ^a   Oikonomou, Evangelos ^a   Vavuranakis, Manolis ^a   Athanasiou, Dimitris ^a   Tourikis, Panagiotis ^a   Gouliopoulos, Nikolaos ^a   Miliou, Antigoni ^a   Mourouzis, Konstantinos ^a   Limperi, Maria ^a   Mazaris, Savvas ^a   Papavassiliou, Athanasios G ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biomarkers; Cardiac remodeling; Cystatin C; Heart failure; Inflammation; Neutrophil gelatinase associated lipocalin; Renal function

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TISSUE REGENERATION;

EID: 84929089750     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140826114656     Document Type: Article

References (40)

1. Ho, K. K.; Pinsky, J. L.; Kannel, W. B.; Levy, D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol., 1993, 22(4 Suppl. A), 6A-13A.
2. Chong, A. Y.; Freestone, B.; Patel, J.; Lim, H. S.; Hughes, E.; Blann, A. D.; Lip, G. Y. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am. J. Cardiol., 2006, 97(5), 671-675.
3. Kannel, W. B. Vital epidemiologic clues in heart failure. J. Clin. Epidemiol., 2000, 53(3), 229-235.
4. Jonsson, S.; Becirovic A. M.; Narfstrom, F.; Melville, J. M.; Hultstrom, M. Renal neurohormonal regulation in heart failure decompensation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2014, 307(5), R493-R497.
5. Lekawanvijit, S.; Krum, H. Cardiorenal Syndrome: Acute Kidney Injury Secondary to Cardiovascular Disease and Role of Protein-Bound Uremic Toxins. J. Physiol., 2014. [Epub ahead of print].
6. Siasos, G.; Tousoulis, D.; Michalea, S.; Oikonomou, E.; Kolia, C.; Kioufis, S.; Synetos, A.; Vlasis, K.; Papavassiliou, A. G.; Stefanadis, C. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr. Med. Chem., 2012, 19(16), 2555-2571.
7. Peralta, C. A.; Katz, R.; Bonventre, J. V.; Sabbisetti, V.; Siscovick, D.; Sarnak, M.; Shlipak, M. G. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinaseassociated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Kidney Dis., 2012 M. G. 60(6), 904-911.
8. Kjeldsen, L.; Johnsen, A. H.; Sengelov, H.; Borregaard, N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem., 1993, 268(14), 10425-10432.
9. Kjeldsen, L.; Bainton, D. F.; Sengelov, H.; Borregaard, N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood, 1994, 83(3), 799-807.
10. Kjeldsen, L.; Cowland, J. B.; Borregaard, N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim. Biophys. Acta, 2000, 1482(1-2), 272-283.
11. Flo, T. H.; Smith, K. D.; Sato, S.; Rodriguez, D. J.; Holmes, M. A.; Strong, R. K.; Akira, S.; Aderem, A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature, 2004, 432(7019), 917-921.
12. Hemdahl, A. L.; Gabrielsen, A.; Zhu, C.; Eriksson, P.; Hedin, U.; Kastrup, J.; Thoren, P.; Hansson, G. K. Expression of neutrophil gelatinaseassociated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 2006, 26(1), 136-142.
13. Tuladhar, S. M.; Puntmann, V. O.; Soni, M.; Punjabi, P. P.; Bogle, R. G. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J. Cardiovasc. Pharmacol., 2009, 53(3), 261-266.
14. Bachorzewska-Gajewska, H.; Malyszko, J.; Sitniewska, E.; Malyszko, J. S.; Pawlak, K.; Mysliwiec, M.; Lawnicki, S.; Szmitkowski, M.; Dobrzycki, S. Could neutrophil-gelatinaseassociated lipocalin and cystatin C predict the development of contrastinduced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press Res., 2007, 30(6), 408-415.
15. Nickolas, T. L.; O'Rourke, M. J.; Yang, J.; Sise, M. E.; Canetta, P. A.; Barasch, N.; Buchen, C.; Khan, F.; Mori, K.; Giglio, J.; Devarajan, P.; Barasch, J. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern. Med., 2008, 148(11), 810-819.
16. Yan, L.; Borregaard, N.; Kjeldsen, L.; Moses, M. A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinaseassociated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem., 2001, 276(40), 37258-37265.
17. Bolignano, D.; Basile, G.; Parisi, P.; Coppolino, G.; Nicocia, G.; Buemi, M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res., 2009, 12(1), 7-14.
18. Grubb, A.; Nyman, U.; Bjork, J.; Lindstrom, V.; Rippe, B.; Sterner, G.; Christensson, A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin. Chem., 2005, 51(8), 1420-1431.
19. Grubb, A.; Bjork, J.; Lindstrom, V.; Sterner, G.; Bondesson, P.; Nyman, U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand. J. Clin. Lab. Invest., 2005, 65(2), 153-162.
20. Villeval'de, S. V.; Gudgalis, N. I.; Kobalava, Zh D. [Cistatin C as a novel marker of renal function impairement and cardiovascular risk]. Kardiologiia, 2010, 50(6), 78-82.
21. Peralta, C. A.; Katz, R.; Sarnak, M. J.; Ix, J.; Fried, L. F.; De Boer, I.; Palmas, W.; Siscovick, D.; Levey, A. S.; Shlipak, M. G. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J. Am. Soc. Nephrol., 2011, 22(1), 147-155.
22. Lang, R. M.; Bierig, M.; Devereux, R. B.; Flachskampf, F. A.; Foster, E.; Pellikka, P. A.; Picard, M. H.; Roman, M. J.; Seward, J.; Shanewise, J.; Solomon, S.; Spencer, K. T.; St John Sutton, M.; Stewart, W. Recommendations for chamber quantification. Eur. J. Echocardiogr., 2006, 7(2), 79-108.
23. Rickham, P. P. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br. Med. J., 1964, 2(5402), 177.
24. Alvelos, M.; Lourenco, P.; Dias, C.; Amorim, M.; Rema, J.; Leite, A. B.; Guimaraes, J. T.; Almeida, P.; Bettencourt, P. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int. J. Cardiol., 2013, 165(1), 51-55.
25. Tousoulis, D.; Oikonomou, E.; Siasos, G.; Chrysohoou, C.; Charakida, M.; Trikas, A.; Siasou, Z.; Limperi, M.; Papadimitriou, E. D.; Papavassiliou, A. G.; Stefanadis, C. Predictive value of biomarkers in patients with heart failure. Curr. Med. Chem., 2012, 19(16), 2534-2547.
26. Van Deursen, V. M.; Damman, K.; Voors, A. A.; Van Der Wal, M. H.; Jaarsma, T.; Van Veldhuisen, D. J.; Hillege, H. L. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ. Heart Fail., 2014, 7(1), 35-42.
27. Dupont, M.; Wu, Y.; Hazen, S. L.; Tang, W. H. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ. Heart Fail., 2012, 5(5), 602-609.
28. Gao, C.; Zhong, L.; Gao, Y.; Li, X.; Zhang, M.; Wei, S. Cystatin C levels are associated with the prognosis of systolic heart failure patients. Arch. Cardiovasc. Dis., 2011, 104(11), 565-571.
29. Shlipak, M. G.; Katz, R.; Sarnak, M. J.; Fried, L. F.; Newman, A. B.; Stehman-Breen, C.; Seliger, S. L.; Kestenbaum, B.; Psaty, B.; Tracy, R. P.; Siscovick, D. S. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med., 2006, 145(4), 237-246.
30. Ordu, S. The prognostic importance of cystatin C in severe systolic dysfunction without chronic kidney disease. Ann. Saudi Med., 2010, 30(6), 495-496.
31. Bolignano, D.; Lacquaniti, A.; Coppolino, G.; Donato, V.; Campo, S.; Fazio, M. R.; Nicocia, G.; Buemi, M. Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2009, 4(2), 337-344.
32. Shrestha, K.; Borowski, A. G.; Troughton, R. W.; Thomas, J. D.; Klein, A. L.; Tang, W. H. Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J. Card. Fail., 2011, 17(6), 472-478.
33. Dharnidharka, V. R.; Kwon, C.; Stevens, G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis., 2002, 40(2), 221-226.
34. Perez-Calvo, J. I.; Ruiz-Ruiz, F. J.; Carrasco-Sanchez, F. J.; Morales-Rull, J. L.; Manzano-Fernandez, S.; Galisteo-Almeda, L.; Pascual-Figal, D. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur. J. Intern. Med., 2012, 23(7), 599-603.
35. Tousoulis, D.; Kampoli, A. M.; Siasos, G.; Stefanadi, E.; Antoniades, C.; Papavassiliou, A. G.; Stefanadis, C. Circulating biomarkers for the diagnosis and prognosis of heart failure. Curr. Med. Chem., 2009, 16(29), 3828-3840.
36. Oikonomou, E.; Tousoulis, D.; Siasos, G.; Zaromitidou, M.; Papavassiliou, A. G.; Stefanadis, C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J. Cardiol., 2011, 52(1), 30-40.
37. Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med., 2008, 358(20), 2148-2159.
38. Zhu, W.; Liu, M.; Wang, G. C.; Che, J. P.; Xu, Y. F.; Peng, B.; Zheng, J. H. Urinary neutrophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis. J. Surg. Res., 2014, 187(1), 237-243.
39. Siasos, G.; Tousoulis, D.; Kioufis, S.; Oikonomou, E.; Siasou, Z.; Limperi, M.; Papavassiliou, A. G.; Stefanadis, C. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr. Top. Med. Chem., 2012, 12(10), 1132-1148.
40. Kiczak, L.; Tomaszek, A.; Bania, J.; Paslawska, U.; Zacharski, M.; Noszczyk-Nowak, A.; Janiszewski, A.; Skrzypczak, P.; Ardehali, H.; Jankowska, E. A.; Ponikowski, P. Expression and complex formation of MMP9, MMP2, NGAL, and TIMP1 in porcine myocardium but not in skeletal muscles in male pigs with tachycardiainduced systolic heart failure. Biomed. Res. Int., 2013, 2013, 283856.